Cancer News and Research

Latest Cancer News and Research

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011

Almac devises new test to detect likelihood of colon cancer recurring

Northern Ireland-based pharmaceutical development company Almac has devised a groundbreaking new test which can detect the likelihood of the recurrence of stage 2 colon cancer in patients who have undergone surgery.

9 Nov 2011

Second molecular conductor discovered in some children with biliary atresia

Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

9 Nov 2011

RWJF announces recipients of 2011 Community Health Leaders Award

The Robert Wood Johnson Foundation is proud to announce today the recipients of its 2011 Community Health Leaders Award, honoring 10 individuals who have overcome daunting odds to improve the health and quality of life for disadvantaged or underserved communities across the country.

9 Nov 2011

Oncothyreon third quarter net income increases to $9.9 million

Oncothyreon Inc. today reported financial results for the third quarter ending September 30, 2011.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

'Second hit' determines immune response against developing Burkitt's lymphoma

The human c-myc gene encodes a transcription factor (MYC) involved in the regulation of a vast number of other genes - it has been estimated that the transcription of about one in six genes is somehow under the control of MYC.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Low uptake of screening and poor awareness of breast cancer symptoms need to be addressed

Fear, anxiety and embarrassment are some of the main barriers preventing women from going for breast screening, but this alone does not account for the variations in uptake, according to new work presented today at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today.

9 Nov 2011

Lapatinib drug could also treat head and neck cancers

A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer - particularly head and neck cancers, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

8 Nov 2011

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Celldex Therapeutics, Inc. today announced initiation of a Phase 1 study of its therapeutic human antibody candidate, CDX-1127, in patients with selected malignant solid tumors or hematologic cancers.

8 Nov 2011

First Edition: November 8, 2011

Today's early morning highlights from the major news organizations, including stories on malpractice reforms and previews of voting in Ohio on two ballot questions affecting health care issues and a Mississippi abortion issue.

8 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

80% of Melbourne tanning salons allow underage customers

According to a recent survey by the Cancer Council Victoria, solarium operators are flouting rules by allowing teenagers under 18 to use sun beds despite laws banning them from doing so.

8 Nov 2011

Stem cell therapy for Parkinson’s

U.S. researchers have finally found a way to overcome difficulties in coaxing human embryonic stem cells to become the neurons killed by Parkinson's disease.

8 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011